GEMCITABINE AN gemcitabine (as hydrochloride) 2 g powder for injection vial

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

gemcitabine hydrochloride, Quantity: 2.28 g (Equivalent: gemcitabine, Qty 2 g)

Commercializzato da:

Juno Pharmaceuticals Pty Ltd

INN (Nome Internazionale):

Gemcitabine hydrochloride

Forma farmaceutica:

Injection, powder for

Composizione:

Excipient Ingredients: sodium hydroxide; sodium acetate; hydrochloric acid; mannitol

Via di somministrazione:

Intravenous

Confezione:

1 vial

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

Gemcitabine Injection is indicated for treatment of patients with locally advanced or metastatic non- small cell lung cancer.,Gemcitabine Injection is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine AN for Injection is also indicated for patients with 5-FU refractory pancreatic cancer.,Gemcitabine Injection, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer.,Gemcitabine Injection, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.,Gemcitabine Injection, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum? based therapy.

Dettagli prodotto:

Visual Identification: White to off-white solid; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius

Stato dell'autorizzazione:

Registered

Data dell'autorizzazione:

2012-04-17